Cargando…
Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis
BACKGROUND: Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guid...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576288/ https://www.ncbi.nlm.nih.gov/pubmed/37833778 http://dx.doi.org/10.1186/s13054-023-04677-2 |
_version_ | 1785121088263421952 |
---|---|
author | Papp, Márton Kiss, Nikolett Baka, Máté Trásy, Domonkos Zubek, László Fehérvári, Péter Harnos, Andrea Turan, Caner Hegyi, Péter Molnár, Zsolt |
author_facet | Papp, Márton Kiss, Nikolett Baka, Máté Trásy, Domonkos Zubek, László Fehérvári, Péter Harnos, Andrea Turan, Caner Hegyi, Péter Molnár, Zsolt |
author_sort | Papp, Márton |
collection | PubMed |
description | BACKGROUND: Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guided AB therapy with standard of care (SOC) in critically ill patients. METHODS: We searched databases CENTRAL, Embase and Medline. We included randomized controlled trials (RCTs) comparing PCT-guided AB therapy (PCT group) with SOC reporting on length of AB therapy, mortality, recurrent and secondary infection, ICU length of stay (LOS), hospital LOS or healthcare costs. Due to recent changes in sepsis definitions, subgroup analyses were performed in studies applying the Sepsis-3 definition. In the statistical analysis, a random-effects model was used to pool effect sizes. RESULTS: We included 26 RCTs (n = 9048 patients) in the quantitative analysis. In comparison with SOC, length of AB therapy was significantly shorter in the PCT group (MD − 1.79 days, 95% CI: -2.65, − 0.92) and was associated with a significantly lower 28-day mortality (OR 0.84, 95% CI: 0.74, 0.95). In Sepsis-3 patients, mortality benefit was more pronounced (OR 0.46 95% CI: 0.27, 0.79). Odds of recurrent infection were significantly higher in the PCT group (OR 1.36, 95% CI: 1.10, 1.68), but there was no significant difference in the odds of secondary infection (OR 0.81, 95% CI: 0.54, 1.21), ICU and hospital length of stay (MD − 0.67 days 95% CI: − 1.76, 0.41 and MD − 1.23 days, 95% CI: − 3.13, 0.67, respectively). CONCLUSIONS: PCT-guided AB therapy may be associated with reduced AB use, lower 28-day mortality but higher infection recurrence, with similar ICU and hospital length of stay. Our results render the need for better designed studies investigating the role of PCT-guided AB stewardship in critically ill patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04677-2. |
format | Online Article Text |
id | pubmed-10576288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105762882023-10-15 Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis Papp, Márton Kiss, Nikolett Baka, Máté Trásy, Domonkos Zubek, László Fehérvári, Péter Harnos, Andrea Turan, Caner Hegyi, Péter Molnár, Zsolt Crit Care Research BACKGROUND: Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guided AB therapy with standard of care (SOC) in critically ill patients. METHODS: We searched databases CENTRAL, Embase and Medline. We included randomized controlled trials (RCTs) comparing PCT-guided AB therapy (PCT group) with SOC reporting on length of AB therapy, mortality, recurrent and secondary infection, ICU length of stay (LOS), hospital LOS or healthcare costs. Due to recent changes in sepsis definitions, subgroup analyses were performed in studies applying the Sepsis-3 definition. In the statistical analysis, a random-effects model was used to pool effect sizes. RESULTS: We included 26 RCTs (n = 9048 patients) in the quantitative analysis. In comparison with SOC, length of AB therapy was significantly shorter in the PCT group (MD − 1.79 days, 95% CI: -2.65, − 0.92) and was associated with a significantly lower 28-day mortality (OR 0.84, 95% CI: 0.74, 0.95). In Sepsis-3 patients, mortality benefit was more pronounced (OR 0.46 95% CI: 0.27, 0.79). Odds of recurrent infection were significantly higher in the PCT group (OR 1.36, 95% CI: 1.10, 1.68), but there was no significant difference in the odds of secondary infection (OR 0.81, 95% CI: 0.54, 1.21), ICU and hospital length of stay (MD − 0.67 days 95% CI: − 1.76, 0.41 and MD − 1.23 days, 95% CI: − 3.13, 0.67, respectively). CONCLUSIONS: PCT-guided AB therapy may be associated with reduced AB use, lower 28-day mortality but higher infection recurrence, with similar ICU and hospital length of stay. Our results render the need for better designed studies investigating the role of PCT-guided AB stewardship in critically ill patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-023-04677-2. BioMed Central 2023-10-13 /pmc/articles/PMC10576288/ /pubmed/37833778 http://dx.doi.org/10.1186/s13054-023-04677-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Papp, Márton Kiss, Nikolett Baka, Máté Trásy, Domonkos Zubek, László Fehérvári, Péter Harnos, Andrea Turan, Caner Hegyi, Péter Molnár, Zsolt Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis |
title | Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis |
title_full | Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis |
title_fullStr | Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis |
title_full_unstemmed | Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis |
title_short | Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis |
title_sort | procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival—a systematic review and meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576288/ https://www.ncbi.nlm.nih.gov/pubmed/37833778 http://dx.doi.org/10.1186/s13054-023-04677-2 |
work_keys_str_mv | AT pappmarton procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT kissnikolett procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT bakamate procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT trasydomonkos procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT zubeklaszlo procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT fehervaripeter procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT harnosandrea procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT turancaner procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT hegyipeter procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis AT molnarzsolt procalcitoninguidedantibiotictherapymayshortenlengthoftreatmentandmayimprovesurvivalasystematicreviewandmetaanalysis |